{"id":"lvgn6051-monoclonal-antibody-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL2109418","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the PD-1 receptor, LVGN6051 prevents cancer cells from evading the immune system, allowing the immune system to attack and destroy cancer cells. This mechanism is similar to other PD-1 inhibitors, which have shown efficacy in various types of cancer.","oneSentence":"LVGN6051 targets the PD-1 receptor to inhibit cancer cell growth and immune evasion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:38:54.000Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT06378177","phase":"PHASE2","title":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"RECRUITING","sponsor":"Lyvgen Biopharma Holdings Limited","startDate":"2024-06-21","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LVGN6051"],"phase":"phase_2","status":"active","brandName":"LVGN6051 Monoclonal Antibody Injection","genericName":"LVGN6051 Monoclonal Antibody Injection","companyName":"Lyvgen Biopharma Holdings Limited","companyId":"lyvgen-biopharma-holdings-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"LVGN6051 targets the PD-1 receptor to inhibit cancer cell growth and immune evasion. Used for Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}